Skip to content

Adjunctive Bright Light Therapy for Patients With Depression

Adjunctive Bright Light Therapy for Patients With Depression at Different Time Period: A Randomized Double-Blind, Placebo-Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04633707
Enrollment
159
Registered
2020-11-18
Start date
2021-03-31
Completion date
2022-07-31
Last updated
2021-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Light Therapy

Keywords

Depression, Bright Light Therapy, Time Period

Brief summary

The study would enroll depressed adolescents and adults with bipolar I or II disorder or major depressive disorder who are receiving stable psychiatric medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling). Participants would be randomly assigned to treatment with either 1,0000-lux bright white light therapy in the morning or 1,0000-lux bright white light therapy in the afternoon, or \<100-lux dim red placebo light therapy in the afternoon (N=59 for each group). Participants would be treated for 6 weeks. Symptoms would be assessed every two weeks with the 24-items Hamilton Depression Scale, the Young Mania Rating Scale, and the Pittsburgh Sleep Quality Index; salivary melatonin and cortisol concentrations will be also measured.

Detailed description

The investigators would divide the participants enrolled into three groups: adjunctive morning bright light therapy (BLT) group (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period of intervention: 7:00\ 9:00 a.m.), adjunctive afternoon BLT group (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period of intervention: 12:00\ 14:00 p.m.), adjunctive placebo therapy group (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period of intervention: 12:00\ 14:00 p.m.).

Interventions

DEVICEadjunctive bright white light therapy in the morning

the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\ 9:00) for 6 weeks.

DEVICEadjunctive bright white light therapy in the afternoon

the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\ 14:00) for 6 weeks.

DEVICEadjunctive dim red light therapy in the afternoon

the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\ 14:00) for 6 weeks.

Sponsors

Guangzhou Psychiatric Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 12-75 years old * Diagnosed using DSM-5 criteria based on the Structured Clinical Interview for Patient Edition (SCID-P) for adults or Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (Kiddie-SADS-PL) for adolescents for the diagnosis of bipolar I or II disorder or major depressive disorder * 24-items Hamilton Depression Rating Scale score ≥ 20, Young Mania Rating Scale score \< 6 * Participants with bipolar disorder taking at least one mood stabilizer, and the types of drugs have not changed in one week; * Antidepressants can be taken, and the types of antidepressants have not changed in one week * Low-dose benzodiazepines can be used, with a maximum of 2 mg of lorazepam equivalent per day * Right-handed * Primary school education or above * Sign informed consents after a full explanation of this study.

Exclusion criteria

* A history of brain organic disease or severe traumatic brain injury and severe physical disease; * Drug, alcohol or other psychoactive substance abusers * Severe suicide risk; * Received modified electric convulsion therapy (MECT) in the past three months * Comorbid with ophthalmic diseases (cataract, macular degeneration, glaucoma, retinitis pigmentosa, etc.) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.) * Taking photosensitive drugs (phenothiazines, antimalarials, propranolol, melatonin, hypericum, stimulants or NSAIDs)

Design outcomes

Primary

MeasureTime frameDescription
response rateup to week 6Participants with a decrease in 24-items Hamilton Depression Scale (HDRS) score of 50% or more from baseline. HDRS is used to measure the depressive severity;its measured time range is within the past week. In this study, version of 24-items is used. The patients are depressed when the total score are greater than 19 points, and there are no depression when the total scores are less than points.

Secondary

MeasureTime frameDescription
manic/hypomanic conversion rateweek 2; week 4; week 6The Young Mania Rating Scale (YMRS) is used to assess manic/hypomanic symptoms and their severity; its measured time range is within the past week. The higher the score, the more severe the symptom. If the total score is greater than or equal to 20, manic episode is considered; if the total score is less than 6, it means there is no manic/hypomanic symptoms.
side effectweek 2; week 4;week 6record the possible adverse reactions
sleep qualityweek 2; week 4;week 6Pittsburgh Sleep Quality Index (PSQI) is used to evaluate sleep quality for last month. It's made of 7 items; every item is scored 1-4 point. Total score is obtained by adding up the points of 7 items. Total score range is 0\ 21 point. The sleep quality is worse when the total score is higher.

Countries

China

Contacts

Primary ContactLin Kangguang, MD;PHD
linkangguang@163.com13560360144
Backup ContactLiu Tao, MD
liutaolp@163.com15017554527

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026